Autopsy report · NCT00977145

Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma

“Closed short of the enrollment goal, due to slow enrollment and adequate data to address endpoints”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• 11 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Craig L Slingluff, Jr

Sponsor type

University, hospital or other

Conditions

Melanoma

Interventions

A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1

Participants

11

Sites

1

Countries

United States

Trials that died the same way

• A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
  “Closed due to slow enrollment” (80% match in meaning)
• Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
  “Study closed due to slow enrollment.” (73% match in meaning)
• Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
  “Closed early due to low enrollment rates” (71% match in meaning)
• Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer
  “The study was closed to enrollment due to slow accrual.” (71% match in meaning)
• Oxford Signature vs. Conventional Global Study
  “Due to slow enrollment and not being able to reach the primary endpoint” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.